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a  b  s  t  r  a  c  t
Transmission  of  excreted  vaccine-derived  infectious  virus  from  vaccinated  to unvaccinated  individuals
is  possible  within  close  contacts.  This  randomized  (1:1),  double-blind  study  evaluated  the  potential  for
transmission  of  human  rotavirus  vaccine  strain,  HRV  (RotarixTM)  from  vaccine  recipients  to  unvaccinated
close  contacts  (twins).  100  pairs  of  healthy  twins  aged  6–14  weeks  at the  time  of Dose  1 of  HRV  vac-
cine/placebo  were  enrolled  and  one  randomly  selected  twin  from  each  pair  received  two  vaccine  doses
and  the  other  received  placebo  doses  (at  2 and  4 months  of  age).  Presence  of  vaccine  strain  in  the  stool  sam-
ples  of  placebo  recipients  was  an  indicator  of  transmission.  Serial  stool  samples  were  tested  for  rotavirus
using  ELISA  at  pre-determined  time  points;  rotavirus  positive  stool  samples  were  tested  with  RT-PCR
and  reverse  hybridization  assay  to  identify  G1P[8]  vaccine  strain.  If G1P[8]  vaccine  strain  was  detected,
the  complete  genome  was  sequenced  to  assess  the  similarity  between  viral  isolates.  Immunogenicity
and  safety  of HRV  vaccine  in transmission  cases  was assessed.  15  transmission  cases  were  reported  in  80
evaluable  twins  who  received  placebo  and  the  transmission  rate  was  18.8%  (95%  CI:  10.9–29.0%).  None  of
the  transmission  cases  was  associated  with  gastroenteritis  symptoms.  Anti-rotavirus  IgA  seroconversion
was  62.5%  (95%  CI: 51.0–73.1%)  (HRV)  and  21.3%  (95%  CI:  12.9–31.8%)  (placebo)  7-weeks  post-Dose  2;
seroconversion  in transmission  cases  was  26.7%  (95%  CI: 7.8–55.1%).  Genetic  variations  or  amino  acid
substitutions  in  transmission  cases  were  similar  to that  seen  in  corresponding  vaccine  recipients.  Trans-
mission  of  HRV  vaccine  strain  to unvaccinated  twins  living  in close  contact  occurred,  however,  they
were  not  associated  with  increased  of  gastroenteritis.  Whether  transmission  leads  to  indirect  protection
viduaamong  unvaccinated  indi
. Introduction
Many earlier studies have demonstrated that rotaviruses, like
ny other enteric viruses are shed in stools and primarily transmit-
ed through fecal-oral route, person-to-person contact and fomites
1,2]. There has been evidence that rotaviruses may  also be trans-
itted to individuals through respiratory droplets [2–4].
The  human rotavirus vaccine strain, HRV mimics natural
otavirus infection, replicates in the intestine of the vaccinated
 Trial  registration number: NCT00396630.
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Open access under CC BY-NC-ND license.ls  remains  unknown  at  this  stage.
© 2011 Elsevier Ltd. 
infants and provides protection against future rotavirus infections
[5]. Studies with the human rotavirus vaccine have demonstrated
that the vaccine virus is shed in the stools of vaccinated infants,
with the peak shedding observed on Day 7 after ﬁrst dose (76–80%
of infants after Dose 1 and 18–29% of infants after Dose 2) [6].
Due  to the shedding of infectious vaccine virus in stools, there
is a theoretical possibility for vaccine virus to be transmitted to
unvaccinated or naive infants—a process similar to that observed
in natural wild-type rotavirus infection [7]. Such transmissions are
possibly expected from any live attenuated vaccines such as oral
polio vaccine [8]. The phenomenon of transmission of the rotavirus
vaccine strain to unvaccinated individuals raises questions about
the safety of the vaccine and the possibility of conferring indirect
protection particularly in developing country settings where the
vaccine coverage might be incomplete as compared to the devel-
Open access under CC BY-NC-ND license.oped countries [9]. The current study was the ﬁrst of its kind
that explored the possibility of horizontal transmission of the HRV
rotavirus vaccine strain from one twin who  received HRV vaccine
to the other twin who  received placebo living under the same
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ousehold. The immunogenicity and safety of the rotavirus vaccine
n transmission cases was also assessed.
. Materials and methods
.1.  Infants and study design
This  phase IIIb, randomized (1:1), placebo-controlled, double-
lind study conducted at one urban site in Santo Domingo,
ominican Republic (106260/NCT00396630). Baseline data from
ll major pediatric hospitals and nurseries was obtained in advance.
arents were informed of the study by presentations at mater-
ity centers, distribution of brochures in health centers and by
roviding information to pregnant women and new parents visit-
ng maternity centers and vaccination sites. Pairs of healthy twins
iving in the same household, aged 6–14 weeks at the time of enrol-
ent, born after a gestational period of ≥32 weeks attending local
rimary healthcare centers, were referred to the site and recruited
y the participating physicians.
From  each pair of twin, one randomly selected twin received
wo oral doses of HRV vaccine and the other received two  placebo
oses at 2 and 4 months of age. Within each pair of twins, Dose 1
nd Dose 2 of HRV vaccine/placebo was administered on the same
ay. In view of providing beneﬁt to the infants receiving placebo
uring the course of the study, an additional dose of HRV vaccine
as administered to all infants (aged < 6 months) at 7-weeks after
he second vaccine/placebo dose in an open-labeled manner. All
nfants received three doses of combined diphtheria, tetanus, acel-
ular pertussis, hepatitis B, inactivated poliovirus and Haemophilus
nﬂuenzae vaccine (DTPa-HBV-IPV-Hib [Infanrix hexaTM, GSK Bio-
ogicals]). Infants were not allowed to take part in the study if they
ad received any investigational drug or vaccine 30 days preced-
ng the ﬁrst study vaccine/placebo dose or had a history of allergic
isease likely to be exacerbated by the vaccine or had a history
f chronic gastrointestinal diseases. They were also excluded if
hey were immunosuppressed or had an acute disease at the time
f study enrolment. Hypersensitivity to the vaccine/placebo and
ntussusception were adverse events that established absolute con-
raindication to further administration of vaccine/placebo doses.
This  study was conducted between January 2007 and February
008, following Good Clinical Practice and the Declaration of
elsinki; the protocol and related documents were reviewed and
pproved by the ethics committee of the study centers. Parents
r guardians of the participating twins provided consent for study
articipation by signing the informed consent form.
.2.  Vaccines
RotarixTM (HRV) vaccine contained at least 106.0 median cell cul-
ure infectious dose of the vaccine strain per vaccine dose (1 ml).
he placebo had the same constituents as the active vaccine but
ithout the vaccine virus and was identical in appearance to
he vaccine. The lyophilized vaccine and placebo were reconsti-
uted with the supplied liquid calcium carbonate buffer before oral
dministration [10].
.3.  Assessment of transmission
Presence  of the vaccine strain in the placebo group for any of
he stool samples collected at pre-determined time points was
onsidered a positive transmission case. To evaluate rotavirus
ntigen shedding (ELISA, Dr. Ward’s Lab, USA), stool samples
ere collected by the parents/guardians in each pair of twins
HRV vaccine/placebo) at pre-determined time points—before the
dministration of the ﬁrst and second HRV vaccine/placebo dose (or
n the day of vaccination), three times a week (every two days) up (2011) 9508– 9513 9509
to six weeks after each dose of HRV vaccine/placebo and at the post-
vaccination blood sampling time point (7 weeks post-Dose 2). To
ensure proper stool sample collection, surveillance was  performed
by a social worker at the time of stool sample collection. The study
staff stuck appropriate labels on the stool collection containers to
avoid mix-up of samples by the parents/guardians.
Stool samples positive for rotavirus in the vaccine recipients
by ELISA suggested the presence of HRV vaccine strain, which in
turn indicated viral shedding. If the placebo recipients were found
rotavirus positive by ELISA, further conﬁrmation for the presence
of HRV vaccine strain was done using the appropriate molecu-
lar technique (e.g. Reverse Polymerase Chain Reaction [RT-PCR],
sequencing). If an ELISA positive stool sample from placebo recipi-
ents for which the vaccine strain is not conﬁrmed, the stool sample
was tested for rotavirus G- and P-type using reverse hybridiza-
tion assay at DDL laboratories, the Netherlands or by any other
appropriate molecular technique (e.g. RT-PCR, sequencing) [11].
If rotavirus vaccine strain was  detected from the twin receiving
placebo, stool samples were further tested to estimate the pres-
ence of infectious viral particles (direct culture of stool samples
on MA-104 cells for which results were expressed qualitatively). If
applicable, full genome of rotavirus was sequenced from twin pairs
receiving placebo or the HRV vaccine to evaluate genetic variation.
2.4. Assessment of immunogenicity
At  pre-vaccination and 7 weeks post-Dose 2 of HRV vac-
cine/placebo, serum samples were collected from all the twins
for the analysis of anti-rotavirus IgA antibody concentration using
ELISA methodology designed by Ward et al. [12,13] at GSK Biologi-
cals Laboratory, Rixensart, Belgium with an assay cut-off of 20 U/ml.
2.5. Assessment of safety
Serious  adverse events and all episodes of gastroenteritis (diar-
rhea [three or more looser than normal stools per day] with or
without vomiting) occurring throughout the study period (until
7-weeks after Dose 2 of HRV vaccine/placebo) were recorded by
the parents/guardians in the dairy cards. In case of a gastroenteritis
episode until 7-weeks after Dose 2, and if the stool sample that is
temporally closest to the onset day of the gastroenteritis episode
is positive for rotavirus by ELISA, then presence of HRV vaccine
strain was evaluated using the appropriate molecular technique
(e.g. RT-PCR, sequencing). If the vaccine strain is not conﬁrmed, the
stool sample was tested for rotavirus G- and P-type using reverse
hybridization assay at DDL laboratories, the Netherlands or by any
other appropriate molecular technique (e.g. RT-PCR, sequencing).
2.6.  Statistical analyses
A  randomization list was  generated at GlaxoSmithKline (GSK)
Biologicals, Rixensart, using a standard SAS® program. A random-
ization blocking scheme (1:1 ratio, block size = 2) was used to
ensure balance between the treatment arms; a treatment num-
ber uniquely identiﬁed the vaccine doses to be administered to the
same infant.
The  study was double-blinded and the parents/guardians of
infants, investigator and the study personnel were unaware of the
study vaccine administered. No investigator or any person involved
in the clinical trial (including laboratory personnel, statisticians and
data management) was aware of the treatment groups during the
course of the study.The  primary analysis of transmission cases and secondary
immunogenicity analysis was  performed on the according-to-
protocol (ATP) cohort for immunogenicity which included all
infants who  complied with the protocol, had immunogenicity data
9510 L. Rivera et al. / Vaccine 29 (2011) 9508– 9513
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withdrawal and elimination of infants from the study at each stage.
Mean age of the twins at the time of Dose 1 of HRV vaccine/placeboFig. 1. Distr
vailable at both blood sampling time points, had no rotavirus in
tool samples collected at pre-determined time points and whose
win was not eliminated from the ATP immunogenicity cohort.
afety was analyzed on the total vaccinated cohort which included
ll infants who had received at least one dose of the HRV vac-
ine/placebo.
The sample size of 200 infants (100 twin pairs) was  planned to
rovide at least 87% power to observe one case of transmission, for
 true transmission rate of ≥2%. The percentage of twins receiving
lacebo with the presence of vaccine strain in at least one stool
ample by ELISA was calculated with exact 95% CI [14]. The occur-
ence of genetic variation in the HRV vaccine strain in the vaccine
nd placebo recipients was described. As the stool samples were
ollected three times a week (every two days), the duration of anti-
en shedding in days was derived as twice the number of rotavirus
ositive stools and was summarized by group. Live viral load in
he twins receiving placebo in the case of transmission was  also
ummarized.
Anti-rotavirus IgA seroconversion rate (anti-rotavirus antibody
oncentration ≥ 20 U/ml in infants initially negative for rotavirus)
nd geometric mean concentrations (GMCs) were calculated with
heir 95% CI [14]. The 95% CI for the mean of log-transformed
oncentration was ﬁrst obtained assuming that log-transformed
alues were normally distributed with unknown variance. The
5% CI for the GMCs were then obtained by exponential-
ransformation  of the 95% CI for the mean of log-transformed titer/
oncentration.n of infants.
Gastroenteritis episodes including severe rotavirus gastroen-
teritis and serious adverse events were tabulated all through the
study period.
2.7.  Role of funding source
This  study was  sponsored and funded by GSK Biologicals. The
sponsor was  involved in all stages of the study, i.e. from study
design to data analysis and writing of the report, and also performed
rotavirus ELISA testing. The corresponding author had full access to
all the data in the study and had ﬁnal responsibility for the decision
to submit for publication.
3.  Results
3.1. Demography
One hundred pairs of twins were enrolled to receive at least
one dose of HRV vaccine/placebo. Fig. 1 describes the reasons for(total vaccinated cohort) was  8.2 weeks (standard deviation: 1.80
weeks). The distribution of male (47.5%) and female (52.5%) infants
was similar in the study groups and all infants belonged to the
American Hispanic or Latino ethnicity.
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Table  1
Summary of the transmission cases.
Transmission
case, N
Previous  dose(s) of
vaccine/placeboa
Twin receiving HRV Twin receiving placebo
Start day of
shedding
Duration of
sheddingb
Day of
transmission
Duration of
sheddinga
Live HRV virus
detected (yes/no)
1 1 Day  4 8 (D4–D16) Day 10 8 (D10–16) Yes
2 1 Day 2 14 (D2–D28) Day 6 14 (D6–D28) No
3 2 Day 8 8 (D8–D32) Day 24 2 (D24) No
4 1 Day 2 14 (D2–D16) Day 14 8 (D14–D20) Yes
5 1 Day 6 16 (D6–D34) Day 10 4 (D10–12) No
6 2 Day 10 4 (D10–D12) Day 12 2 (D12) No
7 2 Day  2 4 (D2–D4) Day 8 2 (D8) No
8 2 Day  2 2 (D2) Day  8 6 (D8–D12) No
9 1 Day 2 14 (D2–D18) Day 14 2 (D14) No
10 2 Day 4 16 (D4–D36) Day 30 2 (D30) No
11 2 Day 10 8 (D10–D16) Day 8 2 (D8) No
12 1 Day 10 2 (D10) Day 8 2 (D8) No
13 1 Day 8 10 (D8–D16) Day 4 4 (D4–D6) Yes
14 1 Day 2 10 (D2–D14) Day 2 10 (D2–D14) No
15 2 Day 6 2 (D6) Day 2 2 (D6) No
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Aa Mean age at Dose 1 was  8.2 ± 1.80 weeks and mean age at Dose 2 was  14.2 ± 1.
b Duration of shedding in days was derived as 2 times the number of RV positive 
ssociated GE symptoms were reported.
.2. Transmission rate
Of  the 80 evaluable placebo-recipient twins, 15 cases of trans-
ission were identiﬁed. The percentage of placebo-recipient twins
ith HRV vaccine strain isolated in at least one stool sample col-
ected at pre-deﬁned time points was 18.8% (95% CI: 10.9–29.0%).
f the 15 transmission cases, eight cases occurred after the ﬁrst
lacebo dose and seven cases occurred after the second placebo
ose. In 10 transmission cases, HRV vaccine strain was  detected
n the stool samples of placebo recipients after the twin receiv-
ng the HRV vaccine had started excreting rotavirus antigen in the
tools. However, in the remaining ﬁve transmission cases, HRV vac-
ine strain was detected in the stool of placebo recipients either
efore or at the same time of the ﬁrst detection of rotavirus antigen
xcretion in the twin receiving the HRV vaccine.
Live virus was identiﬁed in three transmission cases and no gas-
roenteritis symptoms were reported in these infants (Table 1).
amples collected from nine other twins receiving the placebo with
resence of vaccine virus antigen in at least one stool sample were
ested negative for live virus. The stool samples from three other
nfants were not tested for presence of live virus due to insufﬁcient
uantity of the samples. The mean duration of rotavirus shedding
mong the transmission cases was 4.7 days in comparison to 8.8
ays in the corresponding HRV recipients. None of the 15 trans-
ission cases was associated with any gastroenteritis symptoms.
able 2
nti-rotavirus IgA seroconversion rate and GMCs 7-weeks post-Dose 2 of HRV vaccine/pl
HRV group 
Na (nb) %c (95% CId) GMCe value
Overall seroconversion
rate  and GMCs
80  (50) 62.5 (51.0–73.1) 78.6 (50.6–1
GMCs  in seropositive
infants
50  (50) – 271.0 (178.7
Seroconversion rate
and  GMCs in
transmission cases
–  – – 
a N = number of infants with available results.
b n = number of infants with anti-rotavirus IgA concentration ≥ 20 U/ml.
c % = percentage of infants with anti-rotavirus IgA concentration ≥ 20 U/ml.
d 95% CI = 95% conﬁdence interval.
e GMC  = geometric mean antibody concentration.
f One infant presented the HRV vaccine strain and G1P[8] wild type rotavirus strain in eks.
 (the days of the ﬁrst and last sample positive for RV are presented in brackets). No
Most of the rotavirus antigen excretion was observed after Dose
1 of HRV vaccine, with peak excretion observed on Day 6 after
Dose 1 (50.0% of infants) and Day 8 after Dose 2 (18.9% of infants).
Rotavirus excretion at combined time point was observed in 77.5%
(95% CI: 66.8–86.1%) of infants in HRV group.
3.3. Genetic variation
Genetic  sequencing of rotavirus genome in the transmission
cases (placebo group) and in their respective vaccine-recipient
twins revealed that genetic variation was  observed mainly in the
VP4, VP7, NSP3 and NSP4 genes. The random mutation patterns
observed in the transmission cases and their corresponding vaccine
recipients were similar. In addition, the transmission cases did not
raise any safety concerns with respect to rotavirus vaccine strain
reverting to its virulent form or in terms of gastroenteritis episodes.
3.4. Immunogenicity
Anti-rotavirus seroconversion was  observed in 50 (62.5% [95%
CI: 51.0–73.1%]) HRV recipients and 17 (21.3% [95% CI: 12.9–31.8%])
placebo recipients 7 weeks post-Dose 2. Of the 17 infants who sero-
converted in the placebo group, 13 were due to natural infection
and four due to vaccine strain transmission (including one of these
four infants who presented G1P[8] wild type rotavirus strain in
acebo (ATP immunogenicity cohort).
Placebo group
 (95% CI) Na (nb) %c (95% CId) GMCe value (95% CI)
22.2) 80 (17) 21.3 (12.9–31.8) 20.5 (14.5–28.9)
–411.2) 17 (17) – 290.6 (129.5–652.4)
15 (4f) 26.7 (7.8–55.1) 248.3 (46.1–1338.4)
the stool samples.
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he stool samples before vaccine strain transmission). The antibody
oncentrations attained in seropositive infants were 271 U/ml (95%
I: 178.7–411.2) and 290.6 U/ml (95% CI: 129.5–652.4) in the HRV
nd placebo groups, respectively.
Among the 15 transmission cases, four infants (26.7% [95% CI:
.8–55.1%]) were seropositive at post-vaccination blood sampling
ime point (7 weeks post-Dose 2). The anti-rotavirus IgA antibody
MC in these four infants was 248.3 U/ml (95% CI: 46.1–1338.4)
Table 2). The remaining 11 transmission cases had anti-rotavirus
MC < 20 U/ml regardless of virus strain transmission.
.5. Safety
From Dose 1 to study end, at least one rotavirus gastroen-
eritis was reported in 10% (95% CI: 4.9–17.6%) of infants in
RV group (N = 10) and 6% (95% CI: 2.2–12.6%) of infants in the
lacebo group (N = 6). None of the six rotavirus gastroenteritis stool
amples from the placebo recipients contained the HRV G1P[8] vac-
ine strain whereas in the HRV group, G1P[8] vaccine strain was
solated from one gastroenteritis stool sample. Thus, only one possi-
le case of “vaccine associated” gastroenteritis was  observed. Tests
o detect pathogens other than rotavirus in the gastroenteritis stool
amples were not performed. Therefore, all cause gastroenteritis
ith G1P[8] vaccine strain shedding was classiﬁed as rotavirus
astroenteritis.
SAEs were reported in 11 infants (ﬁve in HRV and six in placebo
roups), with bronchiolitis and gastroenteritis being the most com-
on  SAEs. No fatal SAEs, vaccine-related SAEs or intussusception
ere reported in this study.
.  Discussion
It  is important to study the safety of horizontal transmission of
he human live-attenuated rotavirus vaccine virus from the vacci-
ated infants to the infants who received placebo because of the
ossibility of conferring indirect protection or the theoretical con-
ern of the ability of these live viruses to mutate and revert to their
irulent form. Possible transmission of the HRV vaccine strain to
lacebo recipients have been observed in earlier clinical trials in
nfants (5–17 weeks of age at Dose 1) when vaccinated follow-
ng a 0, 1–2 month schedule. In these studies, HRV vaccine strain
as isolated from a total of ﬁve placebo recipients and possible
ransmission may  have occurred in the unvaccinated infants [6,15].
In the present study, twins living in the same house were chosen
ecause these conditions were conducive to analyze the true trans-
ission rate between the pairs of twins. A total of 15 cases (18.8%)
f transmission were observed in the twins that received placebo
ased on the detection of HRV vaccine strain antigen from at least
ne of their stool samples collected. Of these, there were chances
hat ﬁve of the cases were not “true transmission” because in these
ransmission cases the vaccine virus was isolated from the placebo
ecipient either before or at the same time as the antigen excreted
n the stool samples of the corresponding twin receiving the HRV
accine (Table 1). The potential explanation for the detection of
accine virus in the placebo recipients before or at the same time
s the vaccine recipients are—ﬁrstly, the possible mishandling or
ontamination of the stool samples, secondly, ELISA test used was
ot sufﬁciently sensitive to detect low concentrations of the viral
ntigen and thirdly, there could have been a short shedding period
fter vaccine administration (e.g. 1-day, shedding between stool
ample collected).The  genetic variations in terms of random mutation pat-
erns observed in the HRV strain isolated from the stools of
ransmission cases did not result in the rotavirus vaccine stain
everting to its virulent state. None of the transmission cases were (2011) 9508– 9513
associated  with gastroenteritis episodes. In addition, signiﬁcant
number of mutations in the transmission cases were observed in
the previous clinical studies with the HRV vaccine (unpublished
data). These ﬁndings conﬁrm that the HRV vaccine strain was  stable
as demonstrated previously [16].
The phenomenon of transmission has also been observed in
studies with other rotavirus vaccines like RRV-TV [7,17]. In a
study conducted in Venezuela, horizontal transmission of the RRV-
TV vaccine strain to infants receiving placebo was reported in
13% of the total rotavirus gastroenteritis cases. Epidemiological
data collected retrospectively in this trial setting revealed that
among the unvaccinated population the occurrence of rotavirus
diarrhea reduced from 38% to 21% during the vaccination period
[7,17]. This supports the concept of indirect protection, where
the unvaccinated population appeared to beneﬁt from horizontal
transmission.
The peak viral shedding observed in the vaccine recipients
was similar to that observed in an earlier Singaporean study [6].
Although shedding of the vaccine virus strain and transmission
to the placebo or unvaccinated population questions the safety of
the vaccine, the potential beneﬁt of such a phenomenon to the
unvaccinated population through the subsequent protective
immunity offered is often ignored [7]. Indirect protection is espe-
cially critical in poverty-stricken areas of the world where the
vaccine coverage rates are low and the unvaccinated population
may get protection against rotavirus disease without being actively
vaccinated with the rotavirus vaccine.
Immunogenicity results showed that 62.5% (50/80) of infants
in the HRV group and 21.3% (17/80) in the placebo group
seroconverted for anti-rotavirus antibodies. Four infants (4/15;
26.7%) among transmission cases seroconverted during the study.
The remaining 11 transmission cases that did not demonstrate
seroconversion had anti-rotavirus GMC  < 20 U/ml. In this con-
text, it is important to note that seroconversion alone is not
an indicator of protection; however, viral shedding is also an
indicator of protection against rotavirus. Earlier efﬁcacy stud-
ies with HRV vaccine have consistently shown higher vaccine
efﬁcacy against severe rotavirus gastroenteritis even if the sero-
conversion rate was lower [18,19]. Studies conducted in Singapore
[6] and United States [15] identiﬁed HRV vaccine strain in the
gastroenteritis stools of placebo recipients (two each in Singapore
and United States) and anti-rotavirus IgA antibodies in their sera.
These ﬁndings also indicated the occurrence of possible transmis-
sion and subsequent seroconversion in unvaccinated infants.
Similar  random mutation patterns in the vaccine and placebo
recipients, good immunogenicity and the possibility of indirect
protection effect strengthens the position of rotavirus vaccination
as the most beneﬁcial strategy in bringing down the worldwide
rotavirus disease burden.
The  drawbacks of the study are as follows: all stool samples
collected were primarily analyzed by ELISA for detection of
rotavirus antigen; tests for the detection of other pathogens were
not performed. As a result all cause gastroenteritis in infants with
shedding was classiﬁed as rotavirus gastroenteritis. The ELISA test
used for detecting rotavirus shedding in transmission cases may
not be sufﬁciently sensitive to detect low concentrations of the viral
antigen.
The results of this study showed that transmission of the
RotarixTM (HRV) vaccine strain occurred in twins living in the
same household in a developing country. The transmission of the
vaccine strain to the placebo recipients was  not associated with any
safety concerns. Although protection afforded through indirect pro-
tection can be expected theoretically, it remains unknown at this
stage whether transmission of the HRV vaccine strain to unvacci-
nated population could indeed help in reducing rotavirus disease
burden.
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